9 Meters Biopharma (NMTR) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock 9 Meters Biopharma (NASDAQ:NMTR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.40%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$72,500.00Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$11,011.00 Get NMTR Insider Trade Alerts Want to know when executives and insiders are buying or selling 9 Meters Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NMTR Insider Buying and Selling by Quarter 9 Meters Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/21/2023Bethany SensenigCFOSell9,100$1.21$11,011.00 7/6/2022John TemperatoCEOBuy125,000$0.23$28,750.00 7/1/2022Mark A SirgoDirectorBuy175,000$0.25$43,750.00 (Data available from 1/1/2013 forward) NMTR Insider Trading Activity - Frequently Asked Questions Who is on 9 Meters Biopharma's Insider Roster? The list of insiders at 9 Meters Biopharma includes Bethany Sensenig, John Temperato, and Mark A Sirgo. Learn more on insiders at NMTR. What percentage of 9 Meters Biopharma stock is owned by insiders? 2.40% of 9 Meters Biopharma stock is owned by insiders. Learn more on NMTR's insider holdings. 9 Meters Biopharma Key ExecutivesMs. Bethany Sensenig C.M.A. (Age 47)M.B.A., Interim CEO & CFO Compensation: $525.59kDr. Peter H. R. Green M.D.Clinical & Scientific Advisor and ConsultantMr. Joseph A. Murray M.D.Clinical & Scientific Advisor and ConsultantDr. Ciaran P. Kelly M.D.Clinical & Scientific Advisor and ConsultantDr. Elena Verdu M.D.Ph.D., Clinical & Scientific Advisor and ConsultantMr. Markku Mäki M.D.Ph.D., Clinical & Scientific Advisor and ConsultantDr. William J. Sandborn M.D. (Age 60)Ph.D., Clinical & Scientific Advisor and Consultant Dr. Roger Liddle M.D.Clinical & Scientific Advisor and ConsultantDr. Anthony J. Dimarino Jr.Clinical & Scientific Advisor and ConsultantDr. Brian Gordon Feagan FRCPCM.D., M.P.H., Clinical & Scientific Advisor and Consultant More Insider Trading Tools from MarketBeat Related Companies SXTP Insider Trades OGEN Insider Trades EVOK Insider Trades TCRT Insider Trades SBFM Insider Trades MBIO Insider Trades SONN Insider Trades INM Insider Trades CDT Insider Trades GLTO Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:NMTR) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.